The treatment vs. maintenance conundrum raised by Clovis Oncology Inc.'s accelerated approval of Rubraca (rucaparib) therapy for advanced ovarian cancer is nothing new, Robert Coleman, one of the principal investigators in the ARIEL trial program, told BioWorld Today.